|
1
|
Tuttolomondo A, Di Raimondo D, Pecoraro R,
et al: Atherosclerosis as an inflammatory disease. Curr Pharm Des.
18:4266–4288. 2012. View Article : Google Scholar
|
|
2
|
Hulsmans M and Holvoet P: The vicious
circle between oxidative stress and inflammation in
atherosclerosis. J Cell Mol Med. 14:70–78. 2010. View Article : Google Scholar
|
|
3
|
Oyama J, Satoh S, Suematsu N, et al:
Scavenging free radicals improves endothelial dysfunction in human
coronary arteries in vivo. Heart Vessels. 25:379–385. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gamkrelidze M, Mamamtavrishvili N,
Bejitashvili N, et al: Role of oxidative stress in pathogenesis of
atherosclerosis. Georgian Med News. 163:54–57. 2008.PubMed/NCBI
|
|
5
|
Lubos E, Handy DE and Loscalzo J: Role of
oxidative stress and nitric oxide in atherothrombosis. Front
Biosci. 13:5323–5344. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ruilope LM: Telmisartan for the management
of patients at high cardiovascular risk. Curr Med Res Opin.
27:1673–1682. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kurtz TW: Treating the metabolic syndrome:
telmisartan as a peroxisome proliferator-activated receptor-gamma
activator. Acta Diabetol. 42(Suppl 1): S9–S16. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Benson SC, Pershadsingh HA, Ho CI, et al:
Identification of telmisartan as a unique angiotensin II receptor
antagonist with selective PPARgamma-modulating activity.
Hypertension. 43:993–1002. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamagishi S, Matsui T, Nakamura K, et al:
Telmisartan inhibits advanced glycation end products
(AGEs)-elicited endothelial cell injury by suppressing AGE receptor
(RAGE) expression via peroxisome proliferator-activated
receptor-gammaactivation. Protein Pept Lett. 15:850–853. 2008.
View Article : Google Scholar
|
|
10
|
Chaggar PS, Shaw SM and Williams SG:
Review article: Thiazolidinediones and heart failure. Diab Vasc Dis
Res. 6:146–152. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Panchapakesan U, Pollock C and Saad S:
Review article: importance of the kidney proximal tubular cells in
thiazolidinedione-mediated sodium and water uptake. Nephrology
(Carlton). 14:298–301. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bishop-Bailey D and Bystrom J: Emerging
roles of peroxisome proliferator-activated receptor-beta/delta in
inflammation. Pharmacol Ther. 124:141–150. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kilgore KS and Billin AN: PPARbeta/delta
ligands as modulators of the inflammatory response. Curr Opin
Investig Drugs. 9:463–469. 2008.PubMed/NCBI
|
|
14
|
Fernández-Fernández FJ: Telmisartan and
obesity. Intern Med. 49:2191author reply 2193. 2010.
|
|
15
|
Mauro A, Buscemi M and Gerbino A:
Immunohistochemical and transcriptional expression of matrix
metalloproteinases in full-term human umbilical cord and human
umbilical vein endothelial cells. J Mol Histol. 41:367–377. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tumur Z, Shimizu H, Enomoto A, et al:
Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by
oxidative stress-induced NF-kappaB activation. Am J Nephrol.
31:435–441. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Woo CW, Siow YL and Karmin O: Homocysteine
induces monocyte chemoattractant protein-1 expression in
hepatocytes mediated via activator protein-1 activation. J Biol
Chem. 283:1282–1292. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dai J, Wang X, Feng J, et al: Regulatory
role of thioredoxin in homocysteine-induced monocyte
chemoattractant protein-1 secretion in monocytes/macrophages. FEBS
Lett. 582:3893–3898. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cianchetti S, Del Fiorentino A, Colognato
R, et al: Anti-inflammatory and anti-oxidant properties of
telmisartan in cultured human umbilical vein endothelial cells.
Atherosclerosis. 198:22–28. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oyekan A: PPARs and their effects on the
cardiovascular system. Clin Exp Hypertens. 33:287–293. 2011.
View Article : Google Scholar
|
|
21
|
Wang N: PPAR-delta in vascular
pathophysiology. PPAR Res. 2008:1641632008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van Bilsen M and van Nieuwenhoven FA:
PPARs as therapeutic targets in cardiovascular disease. Expert Opin
Ther Targets. 14:1029–1045. 2010.
|
|
23
|
Brunelli L, Cieslik KA, Alcorn JL, et al:
Peroxisome proliferator-activated receptor-delta upregulates 14-3-3
epsilon in human endothelial cells via CCAAT/enhancer binding
protein-beta. Circ Res. 100:e59–e71. 2007. View Article : Google Scholar
|
|
24
|
He H, Yang D, Ma L, et al: Telmisartan
prevents weight gain and obesity through activation of peroxisome
proliferator-activated receptor-delta-dependent pathways.
Hypertension. 55:869–879. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Feng X, Luo Z, Ma L, et al: Angiotensin II
receptor blocker telmisartan enhances running endurance of skeletal
muscle through activation of the PPAR-δ/AMPK pathway. J Cell Mol
Med. 15:1572–1581. 2011.PubMed/NCBI
|
|
26
|
Fan Y, Wang Y, Tang Z, et al: Suppression
of pro-inflammatory adhesion molecules by PPAR-delta in human
vascular endothelial cells. Arterioscler Thromb Vasc Biol.
28:315–321. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hwang SY, Woo CW, Au-Yeung KK, et al:
Homocysteine stimulates monocyte chemoattractant protein-1
expression in the kidney via nuclear factor-kappaB activation. Am J
Physiol Renal Physiol. 294:F236–F244. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Barroso E, Eyre E, Palomer X and
Vázquez-Carrera M: The peroxisome proliferator-activated receptor
β/δ (PPARβ/δ) agonist GW501516 prevents TNF-α-induced NF-κB
activation in human HaCaT cells by reducing p65 acetylation through
AMPK and SIRT1. Biochem Pharmacol. 81:534–543. 2011.
|
